Hims & Hers Weight Loss review: is it worth it?
Hims & Hers offers compounded semaglutide via telehealth, often at a lower monthly cost than brand-name Wegovy.
Best Value
A discontinued shortcut now overtaken by FDA-approved options
Hims & Hers compounded semaglutide gave many people their first affordable, convenient access to a GLP-1 drug during the national shortage. But it was never FDA-approved, the semaglutide shortage was declared resolved in February 2025, and Hims's March 2026 settlement with Novo Nordisk is winding the program down for new patients. If you're starting today, the relevant question is no longer "is compounded worth it" but "which FDA-approved GLP-1 should I use" — and Hims now offers branded Wegovy and Zepbound through the same platform. As with any prescription weight-loss drug, the right choice depends on your health history and should be made with a clinician.
Check PriceFrom $199/mo
Pros
- ✓Made GLP-1 weight loss affordable and accessible during the shortage, often well under half the cash price of branded Wegovy
- ✓Fully telehealth: online consultation, prescription, and home delivery without an in-person clinic visit
- ✓Same active molecule (semaglutide) as Wegovy, backed by strong branded-drug efficacy data for the ingredient (about 15% average loss in the STEP 1 trial)
- ✓Hims now offers FDA-approved branded Wegovy, oral Wegovy, and Zepbound on the same platform, giving existing users a clear path to switch
- ✓Structured monthly subscription bundles medication, clinician messaging, and ongoing dose support in one place
Cons
- ✕Compounded semaglutide is NOT FDA-approved — it skips the agency's review for safety, effectiveness, purity, and potency
- ✕The semaglutide shortage was declared resolved in February 2025, removing the legal basis for routine mass compounding; Hims is discontinuing it for new patients after its March 2026 Novo Nordisk settlement
- ✕Real-world safety signal: the FDA received more than 500 adverse-event reports tied largely to self-injection dosing errors from multi-dose vials, some requiring hospitalization
- ✕Novo Nordisk publicly alleged the active ingredient in such knockoff products was sourced from foreign suppliers whose manufacturing the FDA never authorized, raising sourcing and quality concerns
- ✕Telehealth model means limited in-person medical oversight for a powerful drug with serious contraindications
- ✕Insurance does not cover compounded versions, and branded alternatives may ultimately cost less with coverage and manufacturer savings cards
How it works
Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a gut hormone released after eating. It slows stomach emptying, signals fullness to the brain's appetite centers, and reduces hunger and food "noise," so people tend to eat less. It also stimulates insulin secretion and helps with blood-sugar control. "Compounded" semaglutide is the same molecule custom-mixed by a pharmacy rather than mass-manufactured and FDA-approved like Wegovy or Ozempic. Hims sold it (typically as a self-injected liquid drawn from a multi-dose vial, and later an oral form) under the temporary legal allowance that existed only while branded semaglutide was officially in shortage.
Active ingredient: Compounded Semaglutide
Effectiveness
The efficacy data comes from branded semaglutide, since compounded copies are not separately tested in clinical trials. In the pivotal STEP 1 trial (Wilding et al., NEJM 2021; 1,961 adults), once-weekly injectable semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo, and 86.4% of treated participants lost at least 5% of body weight. The newer oral semaglutide 25 mg (OASIS 4 trial, 64 weeks) showed a mean loss of about 13.6% when counting all randomized participants regardless of whether they stopped treatment, and roughly 16.6% among those who stayed on the drug, versus about 2.4-2.7% with placebo. Compounded products that genuinely contain correctly dosed, properly sourced semaglutide would be expected to perform comparably because it is the same molecule — but their purity, potency, and consistency are not FDA-verified, so individual results and safety can vary.
Side effects
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild-to-moderate, worst when the dose increases, and often easing over time. Less common but serious risks include pancreatitis, gallstones, kidney injury from dehydration, low blood sugar (especially when combined with diabetes medicines), and a boxed warning for thyroid C-cell tumors based on rodent studies. A distinct risk specific to compounded multi-dose vials: the FDA has logged adverse-event reports — more than 500 for compounded semaglutide as of 2025 — tied largely to self-dosing errors, including cases where patients drew 5 to 20 times the intended dose by confusing milligrams, milliliters, and "units," with some events requiring hospitalization. Always confirm the exact dose and units with your prescriber before injecting, and seek medical care if you suspect an overdose.
Cost
Starts at $199/mo from Hims & Hers.
As of 2026, the compounded semaglutide that made Hims popular ran roughly $150-$250 per month, with promotional first-month or longer-plan offers sometimes advertised lower. With the program winding down, new Hims patients are generally directed to FDA-approved options: branded injectable Wegovy and the oral Wegovy pill have been advertised on the platform in roughly the $249-$299/month range and Zepbound somewhat higher (around $399/month), with some lower-cost subscription plans advertised from about $149/month. Crucially, these are cash/subscription prices; with commercial insurance plus a manufacturer savings card, branded Wegovy can drop to as little as $0-$25/month for eligible patients — often making an approved drug cheaper than people expect. Prices change frequently and vary by plan and eligibility; confirm current figures directly with Hims and check your insurance coverage.
Is it worth it?
Compounded semaglutide delivered the same active molecule as Wegovy at a fraction of the price, and many people lost meaningful weight on it. But it skipped FDA review, was tied to more than 500 FDA adverse-event reports driven largely by self-dosing errors, and is now being phased out for new Hims patients after the 2026 Novo Nordisk settlement. New patients should plan on FDA-approved branded GLP-1s, ideally with a clinician's oversight. Discuss your options with a healthcare provider before starting, switching, or stopping any GLP-1 medication.
Frequently asked questions
Is Hims compounded semaglutide FDA approved?
No. Compounded semaglutide is not FDA-approved, meaning the FDA does not review it for safety, effectiveness, purity, or potency before it is sold. Only branded products like Wegovy and Ozempic carry FDA approval; compounded versions were permitted only as a temporary measure during the official semaglutide shortage.
Can I still get compounded semaglutide from Hims in 2026?
Generally no for new patients. After the FDA declared the semaglutide shortage resolved in February 2025 and Hims reached a March 2026 settlement and partnership with Novo Nordisk, Hims is winding down routine compounded semaglutide and directing new patients to FDA-approved branded Wegovy, oral Wegovy, or Zepbound. Compounding is now reserved for limited medically necessary cases, and existing patients should ask Hims about their specific situation.
Is compounded semaglutide as effective as Wegovy?
If it contains correctly dosed, properly sourced semaglutide, it should work similarly because it is the same molecule — branded semaglutide produced about 15% average weight loss in the STEP 1 trial. The catch is that compounded products are not FDA-tested, so their actual potency, purity, and consistency are not guaranteed, and results can vary between products and pharmacies.
Why did Novo Nordisk cut ties with Hims & Hers?
In June 2025, Novo Nordisk terminated its short-lived collaboration with Hims, alleging that Hims engaged in illegal mass compounding disguised as 'personalization' and disseminated deceptive marketing, and raising concerns that knockoff semaglutide ingredients were made by foreign suppliers whose manufacturing the FDA had never authorized. The companies later reached a settlement and a new partnership in March 2026, under which Hims offers Novo's branded products and stops marketing compounded GLP-1s except where medically necessary.
How much does Hims weight loss cost in 2026?
The compounded program historically ran about $150-$250 per month with occasional promotional pricing. New patients are now steered to FDA-approved options, with branded Wegovy and oral Wegovy advertised roughly in the $249-$299 range and Zepbound somewhat higher, and some lower-cost subscription plans from about $149/month. Insurance plus a manufacturer savings card can bring branded Wegovy to as little as $0-$25/month for eligible patients, so check your coverage; prices change frequently.
What are the side effects of semaglutide for weight loss?
The most common are gastrointestinal — nausea, diarrhea, vomiting, and constipation — usually mild and improving over time. Serious but rarer risks include pancreatitis, gallstones, kidney problems from dehydration, and a boxed warning for thyroid tumors seen in rodents. Compounded multi-dose vials also carry a documented risk of dangerous self-dosing errors, so report severe or persistent symptoms to a clinician promptly.
How do you inject compounded semaglutide safely?
Compounded semaglutide usually came in a multi-dose vial requiring you to draw your own dose, so the biggest danger is measuring incorrectly. Always confirm the exact dose in milligrams and the matching syringe volume with your prescriber, never assume 'units' equals milliliters, and follow the once-weekly escalating schedule precisely. The FDA linked hundreds of overdose reports to vial measurement errors, some requiring hospitalization, so check with the prescriber whenever you are unsure.
Should I switch from compounded to branded semaglutide?
For most new patients, an FDA-approved branded GLP-1 is now the safer and more sustainable choice, since it is quality-verified and the compounded supply is being phased out. This is a medical decision: talk to your prescriber about transitioning to Wegovy or another approved drug, and check whether insurance and manufacturer savings cards make the branded version affordable for you.
Sources
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine (PubMed) (2021)
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — U.S. Food and Drug Administration (2025)
- FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize — U.S. Food and Drug Administration (2025)
- Novo Nordisk Terminates Collaboration with Hims & Hers Health, Inc. Due to Concerns About Their Illegal Mass Compounding and Deceptive Marketing — Novo Nordisk via PR Newswire (2025)
- FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss (OASIS 4) — The American Journal of Managed Care (AJMC) (2025)